About TuHURA Biosciences Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://tuhurabio.com/
Frequently Asked Questions
What is the 52-week range for HURA?
The 52-week high is $3.43 and the 52-week low is $0.41.
What is the P/E ratio for HURA?
The P/E ratio data is currently unavailable.
What is the dividend yield for HURA?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -154.27%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.19.
Analyst Recommendation Trends
Wall Street analyst consensus for HURA over the last few months:
Latest HURA News
TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has given clearance to TuHURA's Investigational New Drug (IND) application for its TBS-2025 VISTA-inhibiting antibody for molecularly defined subsets of Acute Myeloid Leukemia (AML) and other blood-related cancers.
FDA Gives Clearance To TuHURA Biosciences' IND Application For TBS-2025 VISTA-Inhibiting Antibody For Molecularly Defined Subsets Of AML And Other Blood-Related Cancers
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that
TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., President and Chief Executive Officer of TuHURA will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-05-28 | Bianco James A. | -150,000 | - | - |
| 2026-02-12 | Tendler Craig | +156,240 | - | - |
| 2026-02-12 | Ng George K | +156,240 | - | - |
| 2026-02-12 | List Alan | +156,240 | - | - |
| 2026-02-12 | MANUSO JAMES S J | +156,240 | - | - |
| 2026-02-12 | Hoffman Robert E. | +156,240 | - | - |
| 2026-01-06 | Dearborn Dan | +273,696 | - | - |
| 2026-01-06 | Bianco James A. | +610,332 | - | - |
| 2025-12-12 | Dearborn Dan | +1,531,367 | - | - |
| 2025-12-12 | Bianco James A. | +3,414,891 | - | - |